A licensed medical provider will review your booking, answer questions, and confirm if the BPC-157 therapy is appropriate for your needs
Patients on metformin and another antihyperglycemic agent (N=229) and patients not on any antihyperglycemic agents (off therapy for at least 8 weeks, N=41) were randomized after a run-in period of approximately 10 weeks on metformin (at a dose of at least 1500 mg per day) in monotherapy
Positive control and negative control Positive control: Select the control strain based on the characteristics of the test sample (such as Staphylococcus aureus, Escherichia coli, etc.), with an inoculation amount of less than 100CFU
The drug has demonstrated an almost complete reduction of liver fat by approximately 75% and helps shed 20% of body weight, both significant results for individuals grappling with fatty liver and obesity
Anyone with a history of pancreatitis, medullary thyroid cancer, or severe gastrointestinal difficulties should discuss this with their provider
